Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658413 | 0.85 | CYP1A2 (0.53) | CYP1A2CYP2A6UHRF1PSMD14COPS5 | |
| SCHEMBL5658382 | 0.77 | GABRP (0.33) | CYP1A2CYP2A6PDPK1 | |
| SCHEMBL5660167 | 0.77 | NCF1 (0.34) | CYP1A2CYP2A6KDM4E | |
| SCHEMBL11149746 | 0.73 | ALDH1A1 (0.37) | CYP2A6CCR1 | |
| SCHEMBL5660696 | 0.73 | TRPV4 (0.40) | — | |
| SCHEMBL5661365 | 0.72 | KMT2A (0.39) | KDM4E | |
| SCHEMBL756551 | 0.71 | CYP2A6 (0.32) | CYP2A6 | |
| SCHEMBL9169786 | 0.71 | CYP2A6 (0.34) | CYP1A2CYP2A6CCR1CCR8 | |
| SCHEMBL5659107 | 0.71 | LCK (0.46) | CYP1A2PSMD14KDM4E | |
| SCHEMBL5657567 | 0.70 | HRH1 (0.37) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506166-B1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131712-A1 | METAL HYBRID COMPOSITE CASTING | Rheinisch-Westfälische Technische Hochschule Aachen (DE) | 2011-10-27 | — | — | WO | claimed |
| US-7678812-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-16 | — | — | US | claimed |
| US-20080097102-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-04-24 | — | — | US | claimed |
| US-6984647-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-10 | — | — | US | claimed |
| EP-1506166-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | claimed |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-25 | — | — | US | claimed |
| WO-2003097586-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | claimed |
| US-4269842-A | Method for treating rhinoviral complaints | RHONE-POULENC INDUSTRIES (FR) | 1981-05-26 | — | — | US | claimed |
| US-4261999-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | RHONE-POULENC INDUSTRIES (FR) | 1981-04-14 | — | — | US | claimed |
| US-4189480-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | RHONE-POULENC INDUSTRIES (FR) | 1980-02-19 | — | — | US | claimed |
| US-8569505-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | disclosed |
| US-8383839-B2 | Heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| EP-1506166-B1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131712-A1 | METAL HYBRID COMPOSITE CASTING | Rheinisch-Westfälische Technische Hochschule Aachen (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2003097586-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
| US-4269842-A | Method for treating rhinoviral complaints | RHONE-POULENC INDUSTRIES (FR) | 1981-05-26 | — | — | US | disclosed |
| US-4269842-A | Method for treating rhinoviral complaints | RHONE-POULENC INDUSTRIES (FR) | 1981-05-26 | — | — | US | disclosed |
| US-4261999-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | RHONE-POULENC INDUSTRIES (FR) | 1981-04-14 | — | — | US | disclosed |
| US-4189480-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC | RHONE-POULENC INDUSTRIES (FR) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097102-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | UTS2R, TRPV1, GPR17 | CYP1A2 1934/4885CYP2A6 1166/4885UHRF1 1019/4885 |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | UTS2R, TRPV6, TRPV1 | CYP1A2 1977/4885CYP2A6 1018/4885UHRF1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.